Factors associated with first-line bevacizumab use in advanced non-squamous non-small cell lung cancer
Journal Title: Journal of Cancer Research & Therapy - Year 2014, Vol 2, Issue 1
Abstract
Introduction: Bevacizumab was approved for treatment of advanced non-squamous, non-small cell lung cancer (NSCLC) in the US in late 2006. Information on its uptake and patient and tumor factors associated with its use is lacking. Materials and methods: This was a longitudinal, retrospective cohort study of patients with stage IIIB/IV non-squamous NSCLC aged 21 years or greater diagnosed between 2005 and 2010 at four Cancer Research Network sites. Patients were categorized as receiving first-line carboplatin-paclitaxel (CP) or carboplatin-paclitaxel-bevacizumab (CPB) within 120 days of diagnosis. Information on patient and tumor characteristics was obtained from queries of sites’ electronic tumor registries and administrative databases. Factors independently associated with CPB use were evaluated using bivariate and multivariate logistic regression analyses. Results: A total of 1109 patients with advanced NSCLC were included with 198 (17.9%) and 911 (82.1%) patients receiving CPB and CP, respectively. Bevacizumab use increased modestly during the study period, peaking in 2008 at 18.5%. In bivariate analyses, patients who received CPB were younger with less comorbidity and well to moderately differentiated tumors while patients who received CP were more likely to have had hypertension, peripheral vascular disease, and a prior hospitalization. Factors independently associated with CPB use included younger age, well/moderately differentiated tumor grade, no prior hospitalization, and more recent study year. Conclusions: Use of bevacizumab in patients with advanced NSCLC increased rapidly then moderated. Younger patients and those with lower risks for adverse effects were more likely to receive bevacizumab.
Authors and Affiliations
Delate T, Won K, Carroll NM, Kushi L, Hornbrook M, Bowles EJA, Menter A, Loggers ET, Ritzwoller D
Keywords
Related Articles
- EP ID EP547272
- DOI 10.14312/2052-4994.2014-1
- Views 80
- Downloads 0
Therapeutic response to a new enzyme-targeting radiosensitization treatment (KORTUC-SC) for patients with chemotherapy-resistant supraclavicular lymph node metastasis
We have developed a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate, part of a method we call “KORTUC II”. This study aimed to evaluate the safety and effectiveness of KORTUC II specifically for p...
Body composition, somatotype and risk of premenopausal breast cancer: a case-control study in Uruguay
In order to analyze detailed anthropometric characterisation for risk of breast cancer (BC) in premenopausal Uruguayan women, a case-control study was carried out at the Pereira Rossell Women’s Hospital, Montevideo, wher...
The positive sentinel lymph node biopsy- can we predict which patients will benefit from further surgery?
Introduction: Although sentinel lymph node biopsy (SLNB) is the gold standard for clinical and radiological negative axillae in breast cancer, the subsequent management of positive nodes is currently under scrutiny with...
Changing trends in gastrointestinal malignancy in Indonesia: The Jakarta experience
Aims: To identify changing trends in gastrointestinal cancer incidence in Indonesia according to age, gender, histopathology, and cancer location. Methods: We examined retrospectively the demography, cancer location, and...
Apocrine carcinoma of the scalp – A case report and highlights for diagnosis
Apocrine sweat gland carcinoma is a rare cutaneous adnexal neoplasm that may occur in the scalp, eyelid, and ear canal. More often, it presents as an asymptomatic, slow-growing, solid or cystic mass with variable color....